Ziftomenib (Komzifti) for Acute Myeloid Leukemia

The medical letter on drugs and therapeutics/The medical letter 2026

View at publisher
DOI: 10.58347/tml.2026.1750e
Cited by: 0

Abstract

Ziftomenib (Komzifti – Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. It is the second oral menin inhibitor to be approved in the US for this indication; revumenib (Revuforj) was approved in October 2025 for use in patients ≥1 year old.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
The medical letter on drugs and therapeutics/The medical letter
Volume
68
Issue
1750
Pages
e48–e49
Publication date
16 March 2026
Language
EN